Intelligent Bio Solutions (INBS) said Thursday that it expects to get its sixth US patent, which would enhance the protection of its lateral flow technology, which is key to intelligence fingerprinting drug testing.
The expected patent grant would enhance Intelligent Bio's current intellectual property portfolio as it prepares to enter the US market this year, the medical technology company said.
Shares of Intelligent Bio were up nearly 4% in recent Thursday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.